• 1. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 2. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 5. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Oligosaccharides
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbohydrates and carbohydrate conjugates Oligosaccharides

Introduction to Mannotetraose (CAS No. 51327-76-5) and Its Emerging Applications in Modern Research

Mannotetraose, a polysaccharide derivative with the chemical formula C₂₄H₃₈O₁₁, is a highly intriguing compound characterized by its unique structural and functional properties. This compound is identified by the CAS number 51327-76-5 and has garnered significant attention in the field of biochemical research due to its potential applications in various therapeutic and diagnostic contexts. The molecular structure of Mannotetraose consists of four mannose units linked together, forming a tetrasaccharide that exhibits remarkable biological activity.

The significance of Mannotetraose lies in its ability to interact with a diverse range of biological receptors and enzymes, which has led to extensive studies exploring its role in modulating immune responses, cell signaling pathways, and metabolic processes. Recent advancements in glycobiology have highlighted the importance of oligosaccharides like Mannotetraose in understanding the complex interactions between pathogens and host cells. This has opened up new avenues for the development of novel therapeutic strategies targeting infectious diseases and chronic conditions.

In the realm of drug development, Mannotetraose has been investigated for its potential as an adjuvant in vaccine formulations. The compound's ability to enhance immune responses by activating pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) has been a focal point of numerous clinical trials. These trials have demonstrated that Mannotetraose can significantly improve the efficacy of vaccine candidates by promoting a robust and sustained immune response. This finding is particularly relevant in the context of emerging infectious diseases, where rapid and effective vaccine development is crucial.

Beyond its immunomodulatory properties, Mannotetraose has also shown promise in the field of regenerative medicine. Studies have indicated that this polysaccharide can stimulate the proliferation and differentiation of stem cells, thereby facilitating tissue repair and regeneration. The molecular mechanisms underlying these effects involve the activation of signaling pathways such as Wnt and Notch, which are critical for maintaining tissue homeostasis. This has led to exploratory research into using Mannotetraose as a therapeutic agent for conditions involving tissue damage and degeneration.

The structural diversity of Mannotetraose allows for modifications that can enhance its pharmacological properties. Researchers have been experimenting with different glycosylation patterns and linkages to optimize its bioavailability and target specificity. These modifications have resulted in derivatives of Mannotetraose that exhibit enhanced stability, reduced immunogenicity, and improved cellular uptake. Such advancements are crucial for translating preclinical findings into effective clinical applications.

The analytical characterization of Mannotetraose (CAS No. 51327-76-5) is another area where significant progress has been made. Modern techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and high-performance liquid chromatography (HPLC) have enabled researchers to elucidate the precise structure and conformational dynamics of this polysaccharide. These analytical methods are essential for ensuring the purity and consistency of Mannotetraose samples used in research and therapeutic applications.

The synthesis of Mannotetraose has also seen notable advancements, with enzymatic approaches becoming increasingly popular due to their high specificity and mild reaction conditions. Enzymes such as glycosyltransferases have been engineered to efficiently construct complex oligosaccharides like Mannotetraose, thereby reducing the reliance on traditional chemical synthesis methods. This shift towards enzymatic synthesis aligns with the growing trend towards green chemistry principles, which emphasize sustainability and environmental responsibility.

In conclusion, Mannotetraose, identified by CAS No. 51327-76-5, is a multifaceted compound with significant potential in various biomedical applications. Its unique structural features, coupled with its ability to modulate biological processes, make it a valuable tool in drug development, vaccine design, and regenerative medicine. As research continues to uncover new aspects of this polysaccharide's biology, it is expected that Mannotetraose will play an increasingly important role in addressing some of the most pressing challenges in modern medicine.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)